Quince Therapeutics, Inc.
QNCX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $77 | $58 | $81 |
| - Cash | $6 | $17 | $8 | $6 |
| + Debt | $0 | $17 | $16 | $15 |
| Enterprise Value | – | $78 | $66 | $89 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$13 | -$16 | -$13 | -$12 |
| % Margin | – | – | – | – |
| Net Income | -$13 | -$16 | -$15 | -$12 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.25 | -0.34 | -0.34 | -0.28 |
| % Growth | 26.5% | 0% | -21.4% | – |
| Operating Cash Flow | -$10 | -$11 | -$10 | -$8 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$10 | -$12 | -$10 | -$8 |